AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06081725 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Playful interactions in an online format
Description: The activity is grounded in dramatic improvisation and comprises several games: a ball game, an association game, a mirror game, a movement story game. The intervention will be conducted by zoom
Study NCT06081725 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: An active control condition in a face-to-face format
Description: The activity consisted of three parts: A structured conversation centered around hobbies. In the second part an exercise in words - singular plural. In the third part, participants will be engaged in a movement practice resembling an exercise class.
Study NCT06081725 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: An active control condition in a face-to-face format
Description: The activity consisted of three parts: A structured conversation centered around hobbies. In the second part an exercise in words - singular plural. In the third part, participants will be engaged in a movement practice resembling an exercise class.
Study NCT05178615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preoperative education
Description: Education about knee anatomy, patophysiology, total knee arthroplasty surgery, pain neurophysiology, management of pain, the importance of exercise
Study NCT04771572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-118
Description: novel, oral, selective treatment for hematological malignancies tested through ascending dose levels
Study NCT05428774 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test product 1
Description: Participants will receive TP1 during one experimental visit.
Study NCT05428774 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test product 2
Description: Participants will receive TP2 during one experimental visit.
Study NCT05428774 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo during one experimental visit.
Study NCT04781803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Cyclosporine 6 mg/kg and mycophenolic acid 1 gram orally on day 0 post-transplant
Study NCT06125652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti Tim-3/CD123 CAR-T cell therapy
Description: Enrolled patients will receive prespecified dose of autologous CAR-T cells.
Study NCT04397679 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D CRT
Study NCT04397679 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy (IMRT)
Description: Undergo IMRT
Study NCT06081725 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: An active control condition in an online format
Description: The activity consisted of three parts: A structured conversation centered around hobbies. In the second part an exercise in words - singular plural. In the third part, participants will be engaged in a movement practice resembling an exercise class. The intervention will be conducted conducted by zoom
Study NCT06081725 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: An active control condition in an online format
Description: The activity consisted of three parts: A structured conversation centered around hobbies. In the second part an exercise in words - singular plural. In the third part, participants will be engaged in a movement practice resembling an exercise class. The intervention will be conducted conducted by zoom
Study NCT04397679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT04397679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Given PO
Study NCT04397679 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields Therapy (TTF)
Description: Undergo TTF
Study NCT05382702 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Test meal description changed
Description: Using a within-subjects crossover design, on two separate mornings participants will eat yogurt described as 'high fat' and 'low fat.' In actuality, the meals will not differ.
Study NCT05785624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vixarelimab
Description: Vixarelimab will be administered as per the schedule specified in the respective arms.
Study NCT05785624 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as per the schedule specified in the respective arms.
Study NCT04899349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Alpelisib (tablets) administered at 300mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 8 in a 28 days cycle.
Study NCT04899349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpelisib
Description: Alpelisib (tablets) administered at 300mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 8 in a 28 days cycle.
Study NCT04899349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant (prefilled syringe) 500mg administered intramuscularly at Cycle 1 Day 1 and 15 after randomization and then at Day 1 of each subsequent cycle during the randomized treatment phase.
Study NCT04899349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant (prefilled syringe) 500mg administered intramuscularly at Cycle 1 Day 1 and 15 after randomization and then at Day 1 of each subsequent cycle during the randomized treatment phase.
Study NCT06081725 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Playful interactions in a face to face format
Description: The activity is grounded in dramatic improvisation and comprises several games: a ball game, an association game, a mirror game, a movement story game.
Study NCT06081725 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Playful interactions in a face to face format
Description: The activity is grounded in dramatic improvisation and comprises several games: a ball game, an association game, a mirror game, a movement story game.
Study NCT04839588 — intervention group
Intervention type: OTHER
Intervention: Usability study
Description: Participants will first be screened for propensity to simulation sickness and for cognitive state using the MoCA evaluation test. Those who passed the screening will perform 4 usability sessions rating the ease of use and perceived benefit of the experimental system and of a caregiver interface laptop. The 2 healthy volunteers will evaluate first, such that issues may be resolved before testing is done on the impaired participants. Each session will be compensated with a $35 payment. During each session participants will play a series of increasing difficulty simulated tasks, aimed to train primarily the executive functions domain. At the end of each session participants will rate their experience using custom subjective evaluation forms with multiple items. Each item will be scored using a 5-point Likert scale. At the end of the 4th session, participants will also fill the USE standardized usability form.~This usability evaluation will be conducted at the NJ Bioscience Center.
Study NCT06129552 — intervention group
Intervention type: PROCEDURE
Intervention: Conchotomy, aesthetic nose surgery or functional endoscopic sinus operation
Description: Conchotomy involves the reduction or removal of hypertrophic nasal turbinates, aesthetic nose surgery is a surgical procedure that aims to enhance the appearance of the nose, while functional endoscopic sinus surgery is a minimally invasive procedure focused on treating sinus conditions by removing obstructions and improving sinus drainage.
Study NCT03720483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine then Placebo
Description: Subject will receive N-acetyl cysteine first followed by Placebo
Study NCT03720483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo then N-acetyl cysteine
Description: Subject will receive Placebo first followed by N-acetyl cysteine
Study NCT04878406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0480-0389
Description: A single dose of subcutaneous NNC0480-0389. The study will last for a maximum of 72 days.
Study NCT05374408 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: BBN for Trauma Informed Care
Description: Brief explanation of BBN will be provided. Patient will be directed to areas of the app that are congruent with treatment focus identified during their standard of care appointment.~Patient will complete by going online or being contacted by a member of the research team member. The research assistant will contact all the patients in 2-3 days to help the patient navigate the BBN and complete the baseline survey if needed.~The patient will continue to meet with their BHP as determined by the standard of care interactions. BHP will highlight features contained in BBN for patient to use in between appointments.~Follow-up phone calls will be scheduled for 2 week and 6 weeks after the initial visit. During these phone- calls the participant will be contacted by a member of the research team to complete follow-up surveys.
Study NCT04695249 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure intervention using 360 degree videos
Description: The intervention consists of eleven sessions. The first five sessions are dedicated to functional assessment and psychoeducation. The second five sessions are dedicated to exposure in 360-degree videos. The last session is provided for relapse prevention.
Study NCT04878406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NNC0480-0389)
Description: A single dose of subcutaneous placebo (NNC0480-0389) The study will last for a maximum of 72 days.
Study NCT04878406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: A single dose of subcutaneous Semaglutide 0.5 mg The study will last for a maximum of 72 days.
Study NCT04878406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Semaglutide)
Description: A single dose of subcutaneous placebo (semaglutide) The study will last for a maximum of 72 days.
Study NCT06530537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: Cilostazol 100mg twice daily
Study NCT06530537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 100mg once daily
Study NCT05300932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Orally take Baricitinib 4mg everyday for 48 weeks
Study NCT05300932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Subject received cyclophosphamide 400mg intravenous drip every 2 weeks combined with oral Prednisone 10-15 mg/d （standard of care）through the 24 weeks double blind period. Subsequently, subject were administered oral Baricitinib 4mg everyday through the 24-48 weeks open label period.
Study NCT05146466 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: E-MATVR
Description: It involves using computer software uploaded onto wireless virtual reality (VR) technology (similar to downloading an app on a mobile phone) and will be delivered using a headset, handheld controllers, and voiceover (all wireless). E-MATVR comprises three serious gaming levels aimed at familiarising men with the normal look and feel of the testes, common testicular symptoms and diseases, and the importance of early help-seeking.
Study NCT05146466 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: E-MATE
Description: It involves using the same information as EMATVR delivered as plain text (e.g., PDF) with still images from E-MATVR. Participants will be given approximately 10 minutes to read the text/look at images using a tablet (e.g., iPad).
Study NCT06344442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine vasopressin
Description: low-dose arginine-vasopressin supplementation group: Vasopressin will be administered by continuous infusion. AVP will be used to a final concentration of 0.12 U/ml. The vasopressor infusion will be titrated to maintain an MAP of at least 65 mmHg. The study-drug infusion will be started at 5 ml/h and increased by 2.5 ml/h to achieve a maximum target rate of 30 ml/h, so that AVP doses ranged from 0.01 to 0.06 U/min.
Study NCT06344442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Norepinephrine will be administered by continuous infusion. Norepinephrine will be used with final concentrations of 120 microg/ml. The vasopressor infusion will be titrated to maintain an MAP of at least 65 mmHg. The study-drug infusion will be started at 5 ml/h and increased by 2.5 ml/h to achieve a maximum target rate of 30 ml/h, so that NE doses ranged from10 to 60 microg/min.
Study NCT05492604 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical examination
Description: Cinical examination carried out during a consultation for the follow-up of the patient
Study NCT05492604 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical examination
Description: Cinical examination carried out during a consultation for the follow-up of the patient
Study NCT04899349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Description: Metformin XR (tablets) administered at a starting dose of 500mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 days cycle. Dose titration from 500 mg once a day to 2000 mg once a day.
Study NCT04899349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin XR
Description: Metformin XR (tablets) administered at a starting dose of 500mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 days cycle. Dose titration from 500 mg once a day to 2000 mg once a day.
Study NCT06374381 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: PEACE Online Resources
Description: The PEACE online resource includes self-paced training modules that cover the foundations of caregiver coaching, caregiver perspectives towards coaching, strategies for aligning with caregivers and gaining buy-in for coaching, evidence-based strategies to empower caregivers from marginalized backgrounds, and strategies to improve collaboration and cohesion among providers working with the same child. Each module includes brief example videos, easy-to read infographics, tip sheets, and checklists to guide implementation. A virtual communication application, Slack, facilitates frequent communication, enhances social networks among providers, and creates social norms related to the use of caregiver coaching. Providers can post questions or suggestions, share resources, and receive updates about other providers' accomplishments. Consultants frequently post encouraging messages and progress updates to increase motivation and shared norms for coaching.
Study NCT06374381 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEACE Weekly Group Facilitation
Description: Facilitation comprises interactive problem solving and support, a shared understanding of need for improvement, and a supportive interpersonal relationship. Providers participate in 12 weekly group facilitation meetings for one hour virtually with an expert consultant focused on auditing providers' fidelity to caregiver coaching through role-play and performance feedback. Each group meeting aligns with content from the PEACE online resource library modules.
Study NCT06374381 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEACE Weekly Individual Facilitation
Description: Individual facilitation is delivered virtually for one hour each week for eight weeks with a consultant focused on reflection and problem solving any identified implementation barriers, as well as practice and performance feedback.
Study NCT05678920 — intervention group
Intervention type: OTHER
Intervention: patient-administered questionnaires
Description: patient-administered questionnaires (MEOWS): Obstetric early warning systems are recommended to provide timely recognition, treatment and early referral of critically ill or developing patients. The development of early warning systems from simple bedside observation charts arose from the knowledge that physiological disturbances precede critical illness. Thanks to these charts, the fact that the patient's findings are in the risky value ranges allows the clinician to evaluate the patient earlier and in detail. MEOWS is a simple screening tool for maternal morbidity.
Study NCT05030857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG4716
Description: From Day 3 to Day 14, participants will receive GLPG4716 tablets once daily in fasted state. On Day 8 GLPG4716 will be administered in fed state.
Study NCT05030857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: On Days 1, 3 and 13, participants will receive a single oral dose of MDZ as an oral solution in fasted state.
Study NCT06546878 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation (Phase I) - nurse intervention
Description: The intervention consists of applying CR program (phase I ) following the Guidlines of American Association of Cardiovascular and Pulmonary Rehabilitation. The program was applied by adapting it to the patient, varying the intensity and frequency of the sessions, according to the FITT_VP acronym.~This phase consists of functional respiratory rehabilitation and motor rehabilitation exercises. Each session is divided into three parts, starting with a warm-up with breathing and isometric exercises, then the so-called peak, which consists of specific endurance/aerobic exercises, and at the end, as a recovery phase, relaxation exercises with stretching are instructed.~Also, health education sessions for patients/caregiver.
Study NCT05492604 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional scales
Description: The Clinical scales are as follows : MRC (Medical Research Scale), ONLS (Overall Neuropathy Limitations Scale), R-ODS (Rasch-built Overall Disability Scale) , INCAT (Inflammatory Neuropathy Cause and Treatment) The functional scales are used as part of the usual care of the patient in the neurology department
Study NCT05492604 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Functional scales
Description: The Clinical scales are as follows : MRC (Medical Research Scale), ONLS (Overall Neuropathy Limitations Scale), R-ODS (Rasch-built Overall Disability Scale) , INCAT (Inflammatory Neuropathy Cause and Treatment) The functional scales are used as part of the usual care of the patient in the neurology department
Study NCT05492604 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Walking test
Description: Walking test over 10 metres at a comfortable speed on the GAITRITE® walkway, fitted with FEETME® soles at the same time. The 10-metre test will be repeated 5 times, with a 2-minute break between each test.
Study NCT05492604 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Walking test
Description: Walking test over 10 metres at a comfortable speed on the GAITRITE® walkway, fitted with FEETME® soles at the same time. The 10-metre test will be repeated 5 times, with a 2-minute break between each test.
Study NCT04899349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin + metformin XR
Description: Dapagliflozin + metformin XR administered as a single tablet combination at a starting dose of 5 mg dapagliflozin + 500 mg metformin XR orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 days cycle. Dose titration from 5 mg dapagliflozin + 500 mg metformin XR orally once daily to 10 mg dapagliflozin + 2000 mg metformin XR once daily
Study NCT04899349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin (tablet) at a starting dose of 5mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 days cycle. Dose titration from 5 mg to 10 mg once daily
Study NCT06235151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper Cu 64 PSMA I&T
Description: Radiopharmaceutical PET imaging tracer injected intravenously for staging of prostate cancer.
Study NCT06446804 — intervention group
Intervention type: OTHER
Intervention: None, pure observationnal study
Description: Pure observatonnal study
Study NCT05664880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: 2 MCG Oral Capsule
Study NCT05664880 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching capsule to 2 MCG Paricalcitol Oral Capsule
Study NCT05832190 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Patients receiving during 3 months before the surgery usual general dietary recommendations regarding balanced diet comprising legumes and fruits, meat or equivalent, dairy products and starch and bread
Study NCT05832190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Patients receiving during 3 months before the surgery usual general dietary recommendations regarding balanced diet comprising legumes and fruits, meat or equivalent, dairy products and starch and bread
Study NCT05832190 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Biotin supplement
Description: 1 capsule per day of Biotin 450µg during 3 months before the surgery.
Study NCT05832190 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber supplement
Description: 3 servings per day of PureLean® Fiber, a powdered blend of fibers and prebiotics, during 3 months before the surgery